1. Why did Novo Nordisk shares rise after Hims dropped its weight loss pill?

Novo Nordisk shares rose because investors saw reduced competition in the weight loss drug market. Hims exiting the low cost pill plan strengthened Novo Nordisk’s pricing power and market dominance.

2. What was the $49 weight loss pill planned by Hims?

Hims planned to sell a compounded weight loss pill priced at $49 per month. The company later scrapped the plan due to regulatory concerns and uncertainty about effectiveness and safety.

3. Does this news benefit Novo Nordisk in the long term?

Yes, it supports Novo Nordisk’s long term outlook. The exit of low cost competitors reinforces demand for branded drugs like Wegovy and Ozempic with proven clinical results.

4. Are there cheaper alternatives to Novo Nordisk weight loss drugs?

Some compounded or off label options exist, but they face regulatory scrutiny. Doctors and regulators generally prefer approved drugs from companies like Novo Nordisk due to safety data.

5. Is Novo Nordisk still the leader in the weight loss drug market?

Yes, Novo Nordisk remains one of the global leaders in obesity treatment. Its drugs have strong clinical backing and high demand, keeping it ahead of many emerging competitors.

US Stocks

Novo Nordisk Shares Gain After Hims Scraps $49 Weight Loss Pill

ByRubaisha February 9, 2026February 9, 2026

Novo Nordisk has once again taken center stage in global markets after its shares moved higher following news that Hims and Hers Health decided to scrap its low cost $49 weight loss pill plan. The update has caught the attention of investors, analysts, and healthcare watchers because it reinforces Novo Nordisk’s strong position in the obesity and diabetes drug market.